Dr.ObesityMed said:Extending the interval and reducing the dose are pharmacologically different.
Pregnancy after maintenance dosing weight loss: stopped GLP-1 medication 5 months before TTC as recommended. Was terrified of regaining weight during pregnancy.
Worked closely with my OB and MFM. Gained 28 lbs during pregnancy (within recommended range). Baby is healthy. The metabolic improvements from pre-pregnancy weight loss gave both of us a healthier pregnancy.
If you're planning pregnancy, discuss the medication discontinuation timeline with your OB. GLP-1 agonists are NOT safe during pregnancy.
One thing that is still open after traveltech_sara’s answer:
Whether extending the interval works as well as reducing the dose, since they are not the same intervention pharmacologically?
josh_phd_bmore said:Pregnancy after maintenance dosing weight loss: stopped GLP-1 medication 5 months before TTC as recommended.
josh_phd_bmore said:...the STEP extension data on maintenance dosing is concerning...
Let me offer a different interpretation of the same data. Yes, 2/3 of weight was regained after discontinuation. But consider:
- This is consistent with EVERY chronic disease medication ever studied
- 1/3 of patients maintained significant weight loss — who are they and why?
- The metabolic improvements partially persisted even with weight regain
- The data supports long-term treatment, not a "course" of therapy
The takeaway isn't "the drug fails when you stop" — it's "chronic diseases require ongoing treatment." We've always known this.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsClosing the loop on my own question.
I went to a lower dose rather than a longer interval on the strength of the trough argument in this thread, and the difference in how even it feels is obvious.
sophie_paris said:josh_phd_bmore said: ...the STEP extension data on maintenance dosing is concerning...
STEP 5 long-term data on maintenance dosing: the 104-week (2-year) extension showed sustained weight loss of -15.2% with continued semaglutide vs weight regain in the discontinuation group[1].
Key insight: weight loss continued to accrue between weeks 68 and 104 in many patients, suggesting the nadir may not occur until year 2+. The 68-week primary endpoint in most trials may underestimate maximal efficacy.
This supports long-term, open-ended treatment rather than fixed-duration "courses" of therapy.
[1] Garvey WT, et al. Nat Med. 2022;28:2083-2091.